Skip to main content

Volume 24 - Issue 7 - July 2016

CRF-SKIRBALL Interventional Innovation Corner
07/07/2016
Didier Tchetche, MD
Clinique Pasteur in Toulouse is the lead center in France for interventional cardiology and cardiology in general, with more than 3000 percutaneous coronary interventions (PCI) per year. I am the head of the structural heart disease program...
Clinique Pasteur in Toulouse is the lead center in France for interventional cardiology and cardiology in general, with more than 3000 percutaneous coronary interventions (PCI) per year. I am the head of the structural heart disease program...
Clinique Pasteur in Toulouse is...
07/07/2016
Cath Lab Digest
CRF-SKIRBALL Interventional Innovation Corner
07/06/2016
CRF-Skirball Interventional Innovation Corner, with section editor Juan F. Granada, MD.
CRF-Skirball Interventional Innovation Corner, with section editor Juan F. Granada, MD.
CRF-Skirball Interventional...
07/06/2016
Cath Lab Digest
CRF-SKIRBALL Interventional Innovation Corner
07/07/2016
Ted Feldman, MD, FSCAI, FACC, FESC
The mitral valve orifice is much bigger than the aortic valve orifice. It is D-shaped, so creating a replacement prosthesis for the mitral valve requires a much bigger device and a much more complex geometry. That is one of the challenges of...
The mitral valve orifice is much bigger than the aortic valve orifice. It is D-shaped, so creating a replacement prosthesis for the mitral valve requires a much bigger device and a much more complex geometry. That is one of the challenges of...
The mitral valve orifice is much...
07/07/2016
Cath Lab Digest
CRF-SKIRBALL Interventional Innovation Corner
07/07/2016
Azeem Latib, MD, BCh, MBBCh
A number of physicians in the world, working alongside some startup companies, have identified an unmet need. We need devices that are percutaneous in order to treat these patients, because they get to a point where surgery is extremely high...
A number of physicians in the world, working alongside some startup companies, have identified an unmet need. We need devices that are percutaneous in order to treat these patients, because they get to a point where surgery is extremely high...
A number of physicians in the...
07/07/2016
Cath Lab Digest
07/07/2016
Jason P. Jundt, MD; Wayne K. Nelson, MD, FACS, RPVI
We have an opportunity to make a meaningful difference, acutely, with relief of pain and swelling, restoration to ambulation, and occasionally, limb preservation. Aggressive treatment of DVT using devices can also minimize the risk of...
We have an opportunity to make a meaningful difference, acutely, with relief of pain and swelling, restoration to ambulation, and occasionally, limb preservation. Aggressive treatment of DVT using devices can also minimize the risk of...
We have an opportunity to make a...
07/07/2016
Cath Lab Digest
07/09/2016
Eric H. Yang, MD
In terms of choosing which GP IIb/IIIa inhibitor to use, what historically has just been a two-person game, is now a three-person game that includes abciximab, eptifibatide, and tirofiban.
In terms of choosing which GP IIb/IIIa inhibitor to use, what historically has just been a two-person game, is now a three-person game that includes abciximab, eptifibatide, and tirofiban.
In terms of choosing which GP...
07/09/2016
Cath Lab Digest
Cath Lab Safety
07/09/2016
Arnold H. Seto, MD, MPA, CCDS, FACC, FSCAI
Healthcare is, like most complex human activities, a team sport. There are many aspects to effective teams including a common purpose, mutual respect, effective leadership and conflict resolution, good communication, situational awareness,...
Healthcare is, like most complex human activities, a team sport. There are many aspects to effective teams including a common purpose, mutual respect, effective leadership and conflict resolution, good communication, situational awareness,...
Healthcare is, like most complex...
07/09/2016
Cath Lab Digest
Cath Lab Spotlight
07/06/2016
Prashant Kaul, MD, FACC, FSCAI; Reginald L. Erwin, RCIS; Brenda McClure, RN, BSN; Cathy Rege, RN, MS
Our median time from arrival to primary PCI for the last 12 months was 38 minutes for patients presenting directly to UNC. For patients transferred from other non-PCI capable facilities, our median time from arrival at the referral facility...
Our median time from arrival to primary PCI for the last 12 months was 38 minutes for patients presenting directly to UNC. For patients transferred from other non-PCI capable facilities, our median time from arrival at the referral facility...
Our median time from arrival to...
07/06/2016
Cath Lab Digest
Clinical Editor's Corner
07/06/2016
Morton J. Kern, MD, MSCAI, FACC, FAHA
No-reflow is usually a devastating complication when treating the ST-elevation myocardial infarction (STEMI) patient or working with saphenous vein graft (SVG) interventions. Fortunately, it’s uncommon for elective procedures. We recently had...
No-reflow is usually a devastating complication when treating the ST-elevation myocardial infarction (STEMI) patient or working with saphenous vein graft (SVG) interventions. Fortunately, it’s uncommon for elective procedures. We recently had...
No-reflow is usually a...
07/06/2016
Cath Lab Digest
CLI Perspectives
07/09/2016
Jihad A. Mustapha, MD, FACC, FSCAI
This month, Dr. Mustapha interviews Osamu Iida, MD, Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
This month, Dr. Mustapha interviews Osamu Iida, MD, Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
This month, Dr. Mustapha...
07/09/2016
Cath Lab Digest